Meyer Handelman Co Lowers stake in Bristol-Myers Squibb Co (BMY)

Bristol-Myers Squibb Co (BMY) : Meyer Handelman Co reduced its stake in Bristol-Myers Squibb Co by 1.58% during the most recent quarter end. The investment management company now holds a total of 810,333 shares of Bristol-Myers Squibb Co which is valued at $61,326,001 after selling 13,000 shares in Bristol-Myers Squibb Co , the firm said in a disclosure report filed with the SEC on Jul 21, 2016.Bristol-Myers Squibb Co makes up approximately 2.67% of Meyer Handelman Co’s portfolio.

Other Hedge Funds, Including , First Quadrant L Pca reduced its stake in BMY by selling 26,300 shares or 47.39% in the most recent quarter. The Hedge Fund company now holds 29,200 shares of BMY which is valued at $2,211,024. Bristol-Myers Squibb Co makes up approx 0.05% of First Quadrant L Pca’s portfolio.Gofen Glossberg Il boosted its stake in BMY in the latest quarter, The investment management firm added 261 additional shares and now holds a total of 42,969 shares of Bristol-Myers Squibb Co which is valued at $3,290,566. Bristol-Myers Squibb Co makes up approx 0.14% of Gofen Glossberg Il’s portfolio.Factory Mutual Insurance Co reduced its stake in BMY by selling 8,000 shares or 1.56% in the most recent quarter. The Hedge Fund company now holds 504,277 shares of BMY which is valued at $38,617,533. Bristol-Myers Squibb Co makes up approx 0.50% of Factory Mutual Insurance Co’s portfolio.

Bristol-Myers Squibb Co closed down -1.81 points or -2.37% at $74.66 with 74,12,412 shares getting traded on Thursday. Post opening the session at $75.41, the shares hit an intraday low of $74.5 and an intraday high of $76.48 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Bristol-Myers Squibb Co reported $0.69 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.66. The company had revenue of $4881.00 million for the quarter, compared to analysts expectations of $4657.63 million. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.

Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Bristol-Myers Squibb Co was Initiated by Hilliard Lyons to “Neutral” on May 23, 2016. Company shares were Reiterated by UBS on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 80 from a previous price target of $73 .Company shares were Reiterated by Barclays on Apr 29, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 75 from a previous price target of $70 .

Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.

Leave a Reply

Bristol-Myers Squibb Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Bristol-Myers Squibb Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.